Radiation
neoadjuvant chemoradiation
neoadjuvant chemoradiation is a radiation therapy with 5 clinical trials. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
RADIATION
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph not_applicable
1
20%
Ph phase_1
1
20%
Ph phase_2
3
60%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(1)
Other(2)
Detailed Status
unknown2
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 23 (60.0%)
N/A1 (20.0%)
Trials by Status
terminated120%
unknown240%
completed240%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_2
Neoadjuvant Chemoradiation for Resectable Glioblastoma
NCT04209790
completednot_applicable
Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients
NCT06631066
unknownphase_2
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
NCT03623737
unknownphase_1
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
NCT02305186
completedphase_2
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
NCT01458717
Clinical Trials (5)
Showing 5 of 5 trials
NCT04209790Phase 2
Neoadjuvant Chemoradiation for Resectable Glioblastoma
NCT06631066Not Applicable
Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients
NCT03623737Phase 2
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
NCT02305186Phase 1
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
NCT01458717Phase 2
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 5